Leerink Partners analyst Puneet Souda maintained a Buy rating on Exact Sciences (NASDAQ:EXAS) Corp. on Thursday, setting a price target of $170, which is approximately 13.05% above the present share price of $150.37.
Souda expects Exact Sciences Corp. to post earnings per share (EPS) of -$1.46 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Exact Sciences, with an average price target of $152.33.
The analysts price targets range from a high of $170 to a low of $140.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $408.36 million and a net profit of $6.28 million. The company's market cap is $25.37 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 45.7% and a 83.19% success rate.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.